Avalglucosidase alfa

(Nexviazyme)

Avalglucosidase alfa

Drug updated on 5/31/2023

Dosage FormInjection (intravenous; 100 mg)
Drug ClassHydrolytic lysosomal glycogen-specific enzyme
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)

Product Monograph / Prescribing Information

Document TitleYearSource
Nexviazyme (avalglucosidase alfa-ngp) Prescribing Information.2021Genzyme Corporation Cambridge, MA

Systematic Reviews / Meta-Analyses